This topic contains a solution. Click here to go to the answer

Author Question: What is the fate of excess dietary protein? a. After absorption, the liver will store the extra ... (Read 59 times)

P68T

  • Hero Member
  • *****
  • Posts: 509
What is the fate of excess dietary protein?
 a. After absorption, the liver will store the extra amino acids
  b. After absorption, the extra amino acids will be rapidly degraded
  c. Digestion will be decreased by 30 to 60, resulting in less absorption
  d. After absorption, extra proteins will be synthesized and stored for use when protein intake returns to normal

Question 2

What is most likely to occur when a calcium supplement and an iron supplement are taken simultaneously?
 a. Absorption of iron is reduced
  b. Absorption of iron is improved
  c. Excretion of iron in the urine is reduced
  d. Excretion of iron in the urine is enhanced



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

Fayaz00962

  • Sr. Member
  • ****
  • Posts: 330
Answer to Question 1

b

Answer to Question 2

a





 

Did you know?

The U.S. Pharmacopeia Medication Errors Reporting Program states that approximately 50% of all medication errors involve insulin.

Did you know?

Stevens-Johnson syndrome and Toxic Epidermal Necrolysis syndrome are life-threatening reactions that can result in death. Complications include permanent blindness, dry-eye syndrome, lung damage, photophobia, asthma, chronic obstructive pulmonary disease, permanent loss of nail beds, scarring of mucous membranes, arthritis, and chronic fatigue syndrome. Many patients' pores scar shut, causing them to retain heat.

Did you know?

By definition, when a medication is administered intravenously, its bioavailability is 100%.

Did you know?

The newest statin drug, rosuvastatin, has been called a superstatin because it appears to reduce LDL cholesterol to a greater degree than the other approved statin drugs.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library